Home › Squamous Cell Carcinoma ng Ulo at Leeg › South Carolina › Charleston
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Charleston, SC
14 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Charleston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Nagre-recruitPhase 2/3
- Site#0104, Charleston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Nagre-recruitPhase 3
- Medical University of South Carolina, Charleston
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
- Medical University of South Carolina, Charleston
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
Nagre-recruitPhase 2
- Medical University of South Carolina, Charleston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Nagre-recruitPhase 1
- Normunity Investigational Site, Charleston
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Nagre-recruitPhase 2/3
- Medical University of South Carolina, Charleston
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
Nagre-recruitPhase 2
- Medical University of South Carolina Hollings Cancer Center, Charleston
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 3
- GSK Investigational Site, Charleston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 2
- USA03-0, Charleston
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
Nagre-recruitPhase 2
- Medical University of South Carolina, Charleston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 3
- Medical University of South Carolina (MUSC), Charleston
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
Nagre-recruit
- Medical University of South Carolina, Charleston
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 123, Charleston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Nagre-recruitPhase 1
- Medical University of South Carolina, Hollings Cancer Center, Charleston
Pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg sa ibang lungsod
- Houston, TX47 pag-aaral
- Los Angeles, CA42 pag-aaral
- Boston, MA40 pag-aaral
- New York City, NY39 pag-aaral
- Nashville, TN39 pag-aaral
- St. Louis, MO28 pag-aaral
- Arlington, VA26 pag-aaral
- Philadelphia, PA26 pag-aaral
- Chicago, IL26 pag-aaral
- Atlanta, GA24 pag-aaral
- San Antonio, TX22 pag-aaral
- New Haven, CT22 pag-aaral
Iba pang pag-aaral sa Charleston
- Depression19 pag-aaral
- Stroke18 pag-aaral
- Pagkabigo ng Puso18 pag-aaral
- Non-Small Cell Lung Cancer16 pag-aaral
- Post-Traumatic Stress Disorder16 pag-aaral
- Sakit sa Puso at Ugat ng Dugo15 pag-aaral
- Kanser sa Prostate15 pag-aaral
- Kanser (lahat ng uri)14 pag-aaral
- Sakit ni Parkinson13 pag-aaral
- Interstitial Lung Diseases13 pag-aaral
- Kanser sa Suso12 pag-aaral
- Kanser sa Baga11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.